GENERALIZED PUSTULAR PSORIASIS
Clinical trials for GENERALIZED PUSTULAR PSORIASIS explained in plain language.
Never miss a new study
Get alerted when new GENERALIZED PUSTULAR PSORIASIS trials appear
Sign up with your email to follow new studies for GENERALIZED PUSTULAR PSORIASIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug shows promise for rare, severe skin condition
Disease control CompletedThis study tested a drug called imsidolimab in 8 adults with active generalized pustular psoriasis (GPP), a rare and serious skin disease. The goal was to see if the drug could improve skin symptoms and reduce pustules. Results showed that most participants had meaningful improve…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE2 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 07:56 UTC
-
New drug shows promise for rare, severe psoriasis flares
Disease control CompletedThis study tested a new drug called imsidolimab in 45 adults with generalized pustular psoriasis (GPP), a rare and serious skin condition that causes painful pus-filled bumps. Participants received either the drug or a placebo to see if the drug could clear or nearly clear their …
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE3 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 07:23 UTC
-
New drug offers hope for rare, severe skin Flare-Ups
Disease control CompletedThis study gave a single infusion of a medicine called spesolimab to 39 people in China with a serious skin disease called generalized pustular psoriasis (GPP) who had no other treatment options. The goal was to control the flare-up, not to cure the disease. Participants were mon…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Real-World check: Spesolimab's safety tracked in 52 GPP patients
Disease control CompletedThis study looked at how safe and effective the drug spesolimab is for people with a severe skin condition called generalized pustular psoriasis (GPP) who have sudden flare-ups. Researchers tracked 52 patients in Japan who were starting spesolimab for the first time, recording an…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
Breakthrough injection may stop dangerous skin flares before they start
Prevention CompletedThis study tested whether a medicine called spesolimab can prevent flare-ups of generalized pustular psoriasis (GPP), a rare and serious skin condition. It included 123 people aged 12 to 75 whose skin was clear or nearly clear at the start. Participants received either a placebo …
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Prevention
Last updated May 19, 2026 11:59 UTC
-
New shot clears painful pustules in days for rare skin condition
Symptom relief CompletedThis study tested a single dose of a drug called spesolimab in 53 people with a rare and severe type of psoriasis that causes painful pus-filled blisters all over the body. The goal was to see if it could quickly clear these blisters within one week compared to a placebo. The dru…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Symptom relief
Last updated May 26, 2026 07:49 UTC